by Barry101 | Jan 8, 2019 | Press Release
The Phase II Study Will Combine Hemispherx’s Ampligen with KeytrudaOCALA, Fla., Jan. 08, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology,...
by Barry101 | Jan 2, 2019 | Press Release
Second Large Shipment Dispatched to Second Major ClinicOCALA, Fla., Jan. 02, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, shipped 325...
by Barry101 | Dec 26, 2018 | Press Release
OCALA, Fla., Dec. 26, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) continues to work with Apple and other affected parties for a solution to correct Apple iOS12 Stocks Application misinformation and enable investors using the Apple device for their...
by Barry101 | Dec 19, 2018 | Press Release
OCALA, Fla., Dec. 19, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, shipped 720 vials of Ampligen to the Myalgic Encephalomyelitis/Chronic...
by Barry101 | Dec 17, 2018 | Press Release
Highlights Include Visit with Patients in North CarolinaOCALA, Fla., Dec. 17, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, recently met with...
by Barry101 | Dec 12, 2018 | Press Release
Business Update and Apple iOS Stocks AdvisoryOCALA, Fla., Dec. 12, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB) announces that Thomas K. Equels, President and Chief Executive Officer, has issued a Letter to Stockholders providing a business update. The...
